Oncology Corporate Profile
Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, MD. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for clinical success in genetically defined patient populations.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|Loxo-101||tropomyocin receptor kinase A (TrkA) inhibitor||Various cancer types||II|
|Loxo-101||tropomyocin receptor kinase A (TrkA) inhibitor||Sarcoma||I|
View additional information on product candidates here »
4/3/2017 10:02 am
4/2/2017 08:03 pm
3/31/2017 08:03 pm
[GlobeNewswire] - STAMFORD, Conn., March 31, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced ...